

Relationships With Industry and Other Entities (Comprehensive)—2014 ACC/AHA Focused Update of Secondary Prevention Lipid Measures

Committee Member	Employment	Consultant	Speaker	Ownership/ Partnership/ Principal	Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Joseph P. Drozda, Jr. (Chair)	Mercy Health — Director of Outcomes Research	None	None	None	<ul style="list-style-type: none"> • U.S. Food and Drug Administration† 	<ul style="list-style-type: none"> • AMA PCPI-Executive Committee* • Boston Scientific Rhythm† 	None
T. Bruce Ferguson, Jr.	Brody School of Medicine at ECU Dept. of Cardiovascular Sciences	None	None	<ul style="list-style-type: none"> • RFPi, LLC* 	<ul style="list-style-type: none"> • NIH-ISCHEMIA trial • Novadaq Technologies, Inc.† 	<ul style="list-style-type: none"> • Edwards Laboratories-PARTNERS Trial • Society of Thoracic Surgeons* 	None
Hani Jneid	Baylor College of Medicine MEDVAMC	None	None	None	None	None	None
Harlan M. Krumholz	Yale University School of Medicine	<ul style="list-style-type: none"> • Premier, Inc.† • Institute for Healthcare Improvement 	None	None	<ul style="list-style-type: none"> • Agency for Healthcare Research and Quality† • Catherine and Patrick Weldon Donaghy Medical Research Foundation† • Fuwai Hospital, Beijing • Johnson & Johnson† • Medtronic, Inc.† • National Cancer Institute† • National Heart, Lung, and Blood Institute† • Robert Wood Johnson Foundation† • The Commonwealth Fund† • U.S. Food and Drug Administration† 	<ul style="list-style-type: none"> • American Board of Internal Medicine • American Heart Association† • Cardiovascular Outcomes* • ImageCOR • Massachusetts Medical Society† • Patient-Centered Outcomes Research Institute (PCORI)† • UnitedHealth† • VHA, Inc.† 	None
Brahmajee K. Nallamothu	University of Michigan—Assistant Professor Internal Medicine, Division of Cardiology	<ul style="list-style-type: none"> • Abbott • UnitedHealth 	None	None	<ul style="list-style-type: none"> • NIH † • VA HSRD† 	<ul style="list-style-type: none"> • American Heart Association* • European Society of Cardiology* 	None
Jeffrey W. Olin	Mt. Sinai School of Medicine	<ul style="list-style-type: none"> • Fibromuscular Dysplasia Society 	None	<ul style="list-style-type: none"> • Northwind† 	<ul style="list-style-type: none"> • Astra Zeneca† 	<ul style="list-style-type: none"> • Astra Zeneca 	None

		of America (Non Profit)* • Merck • Novartis • Plurestem					
Henry H. Ting	New York-Presbyterian Hospital/Columbia University Medical Center	None	None	None	None	None	None

This table represents all relationships of committee members with industry and other entities. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of \$10,000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.

*No financial relationship.

†Significant (greater than \$10,000) relationship.